The Company

Scientific Board

Professor Anthony Hollander, Chairman of the Scientific Board

Anthony Hollander graduated with 1st Class Honours in Pharmacology (University of Bath) and a PhD in Pathology (The University of Bristol). Anthony then spent 3 years working as a Canadian Arthritis Society Postdoctoral Research Fellow at McGill University, Montreal, Canada, where he developed new antibodies and assays for specific forms of degraded cartilage collagen.

In 1993 Anthony was appointed as a UK Arthritis Research Campaign Postdoctoral Fellow and Lecturer at the University of Sheffield. Anthony was promoted to Reader in 1999 and in 2000, at the age of 36, he was appointed to the Chair of Rheumatology & Tissue Engineering at The University of Bristol. This was the first time that a non-clinical scientist had been appointed to a Chair of Rheumatology in the UK and reflected the community's willingness to support his vision of translating basic research into therapeutic advances.

During his research career Anthony has published over 70 papers in peer-reviewed journals and raised research funding from government, EU, charities and industry to a total of almost £4 million. Anthony sits on grant review boards for the government (stem cell panel) and the EU (biomaterials and stem cell panels). Anthony is a member of the editorial board of 2 journals ("International Journal of Experimental Pathology" and "Regenerative Medicine"). Anthony was Honorary Secretary of the British Society for Matrix Biology from 2003 until 2007.

Anthony is a Fellow of the International cartilage Repair Society (ICRS) and Chair of the ICRS Communications Committee. Anthony has just been invited to become a Fellow of the Royal College of Medicine. Anthony is frequently invited to speak at National and International meetings and has appeared on television and radio as well as featuring in newspaper reports around the world.

Professor Molly Stevens

Molly Stevens is currently Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Institute of Biomedical Engineering. She joined Imperial in 2004 after a Postdoctoral training in the field of tissue engineering with Professor Robert Langer in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT). Prior to this she graduated from Bath University with a first class honours degree in Pharmaceutical Sciences and was then awarded a PhD in biophysical investigations of specific biomolecular interactions and single biomolecule mechanics from the Laboratory of Biophysics and Surface Analysis at the University of Nottingham (2000).

In 2009 she was awarded the Jean Leray Award from the European Society for Biomaterials, in 2007 the prestigious Conference Science Medal from the Royal Pharmaceutical Society and in 2005 the Philip Leverhulme Prize for Engineering. She has also recently been recognised by the TR100, a compilation of the top innovators, under the age of 35, who are transforming technology - and the world with their work. Her previous awards include the Ronald Belcher Memorial Lecture Award from the Royal Society of Chemistry (2000) and both the Janssen Prize and the UpJohn Prize for academic excellence and research.

She has a large and extremely multidisciplinary research group of students and postdocs/fellows. Research in regenerative medicine within her group includes the directed differentiation of stem cells, the design of novel bioactive scaffolds and new approaches towards tissue regeneration. She has developed novel approaches to tissue engineering that are likely to prove very powerful in the engineering of large quantities of human mature bone for autologous transplantation as well as other vital organs such as liver and pancreas, which have proven elusive with other approaches. This has led to moves to commercialise the technology (she is the co-founder of BioCeramic Therapeutics) and set-up a clinical trial for bone regeneration in humans. In the field of nanotechnology the group has current research efforts in exploiting specific biomolecular recognition and self-assembly mechanisms to create new dynamic nano-materials, biosensors and drug delivery systems.

Professor Allen Goodship

Professor Allen Goodship has held several major appointments before commencing as Director of the Institute of Orthopaedics and Musculo-Skeletal Science in January 2000. At Bristol University he held the post of Head of the Department of Anatomy in the Medical Faculty and in 1996 was given the unique joint appointment with the Royal Veterinary College and University College London as the Professor of Orthopaedic Sciences.

Although a veterinary graduate, Professor Goodship's research interests are centred around the response of skeletal tissues to functional stimulation. His main areas of research are in relation to bone remodelling and repair; tendon and ligament injury; degeneration of the intervertebral disc; in vivo tissue engineering, particularly in relation to manipulating skeletal tissues in the body to resurface joints and in the improvement of osseo-mechanical integration of joint prostheses. In many of these conditions there are great similarities between animals and man, for instance the pathology of tendon injury in racehorses is very similar to the changes seen in human Achilles tendon lesions and in lesions of the rotator cuff in the shoulder.

Professor Goodship is looking to expand and develop the research activity undertaken in the Institute of Orthopaedics and Musculo-Skeletal Science, and to increase levels of external research funding - that will benefit both the Royal National Orthopaedic Hospital (RNOHT) in terms of its bid for Support for Science and the University. At the time of Professor Goodship's appointment as Director of the Institute, UCL indicated commitment and support for the retention and expansion of the Institute, following the decision for the RNOHT to remain at the Stanmore site. Since this time there have been major redevelopments in the Institute, most notably the upgrading of the laboratory facilities and the student centre.

Professor Goodship also has plans to build on the Institute's eminent role in education and stressed the importance of education at both undergraduate and postgraduate level. Several important advances have already been implemented such as the appointment of five new lecturers, an increase in PhD studentships, a review of the Intercalated BSc in Orthopaedic Science and MSc in Orthopaedic courses and an increase in the intake of BSc students. Professor Goodship is also looking forward to developing more joint courses in Continuing Professional Development with the Teaching Centre. Professor Goodship sees this as an exciting time to build on the strengths of the Institute and the links with both RNOHT and SIW. He looks forward to the possible incorporation of the Institute as an integral component of the modernisation and redevelopment of the Hospital.

Professor Richard O. C. Oreffo

Richard Oreffo holds the chair of Musculoskeletal Science and is co-founder of the Centre for Human Development, Stem Cells & Regeneration. He is Associate Dean for Innovation and Enterprise within the Faculty of Medicine, Health and Life Sciences, University of Southampton. Richard graduated from the University of Liverpool and University of Oxford with degrees in Biochemistry and a doctorate in Bone Physiology. After three years in San Antonio Texas, with Professor Greg Mundy working on Bone Remodeling, Richard returned to England to establish a bone research programme at Zeneca Pharmaceuticals in the emerging Bone group followed by a return to the Nuffield Orthopaedic Centre in Oxford. In 1999, Richard was appointed to a lectureship at the University of Southampton. He was awarded the Maxime Hanns award in 2001 and a readership and Personal chair in musculoskeletal science in 2004.

Richard leads a multidisciplinary research group (see www.skeletalstemcells.org) centred on i) understanding human skeletal stem cell biology and regenerative approaches for skeletal repair and, ii) elucidating the role of fetal programming as a consequence of maternal nutritional challenge on mesenchymal progenitor cell activity, potential and bone function with age. The group is currently developing translational strategies for clinical application and much of the work is undertaken in multidisciplinary programs in collaboration with clinicians, bio-engineers, modelers and bone biologists both in the UK as well as international collaborations.

Richard is currently a member of the BBSRC Healthy Organism Panel, UK National Stem Cell Network Advisory Committee, ARC Research Committee, and MRC Stem Cells Basic Science Liaison Committee. He was former Honorary Treasurer of the British Orthopaedic Research Society (2000-2004) and committee member of the Bone Research Society (2003-2006). Richard currently serves on the editorial boards of the journals ‘European Cells and Materials’ and ‘Regenerative Medicine’ and “Journal of Tissue Engineering.” He has published over 130 peer-reviewed papers and 20 contributed reviews/book chapters. In 2008 he was appointed to the Research Council for Health of the Academy of Finland and in 2009 he was elected a Fellow of the Institute of Biology.

HOME ο THE COMPANY ο TECHNOLOGY ο PARTNERING AND LICENSING ο INVESTORS ο PRESS ο CONTACT ο SITE MAP ο PRINT THIS PAGE ο LOG-IN

Registered Address: The Walbrook Building, 25 Walbrook, London EC4N 8AF | Company reg. no. 6447 651

© 2017 Azellon